Inlife Ltd.
Inlife Ltd. is a company specializing in the development, production, and distribution of health and wellness products. Its primary function is to provide consumers with supplements and related health products designed to enhance overall well-being and address specific health concerns. Inlife Ltd. serves various sectors, including dietary supplements, sports nutrition, and healthcare, playing a key role in the consumer health industry. The company's offerings often include vitamins, minerals, herbs, and functional nutrition products, aligning with consumer preferences for natural and science-backed wellness solutions. Inlife Ltd. impacts the healthcare and lifestyle markets by promoting preventive health measures and supporting active, wellness-oriented lifestyles. Its presence is significant in regions where awareness and demand for health supplements are rising, contributing to broader trends in health-conscious consumer behavior. Through its innovative approach to product development and market reach, Inlife Ltd. supports the growing emphasis on integrated health management and personalized wellness solutions.
$2.55
-$0.10 (-3.77%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-31.60% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 16.5%, still solid. Margins contracted 39.8pp, which offsets some of the top-line progress.
Free cash flow declined 234% versus the prior year, cash generation momentum has weakened. ROIC dropped from 9.27% to -25.73%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$18M
▲ +16.5% YoY
Net Income (TTM)
-$5M
▼ -439.0% YoY
Op. Margin
-31.60%
▼ -39.8pp YoY
ROIC
-25.73%
▼ -35.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -234.1% YoY
Op. Cash Flow (TTM)
-$2M
▼ -214.5% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$7M
3Y CAGR: +40.4%
Continue Research
Is Inlife (INLF) overvalued?
Inlife (INLF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Inlife scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Inlife a high-quality business?+
Inlife scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -31.6% operating margin and a -25.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Inlife a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh INLF's valuation and scores 35/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Specialty Industrial Machinery
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.